Weight loss plus vitamin D reduce cancer-linked chronic inflammation
the ONA take:
According to a new study published online ahead of print in the journal Cancer Prevention Research, researchers at Fred Hutchinson Cancer Research Center in Seattle, Washington, have found that the addition of vitamin D supplementation to weight loss had a greater improvement in chronic inflammation compared with weight loss alone.
Chronic inflammation is known to contribute to the development and progression of some cancers, as well as other diseases.
For the study, researchers enrolled 218 healthy, overweight, postmenopausal women who had insufficient vitamin D levels. All participants participated in a diet and weight loss program and half were randomly assigned to receive vitamin D 2,000 IU daily for 1 year.
Results showed that women who lost 5 to 10% of their body weight and took vitamin D supplementation experienced the greatest reduction in chronic inflammation.
"We were quite surprised to see that vitamin D had an effect on an inflammation biomarker only among women who lost at least 5 percent of their baseline weight," Catherine Duggan, Ph.D., a principal staff scientist in the Public Health Sciences Division at Fred Hutchinson Cancer Research Center said. "That suggests vitamin D can augment the effect of weight loss on inflammation."
Addition of vitamin D supplementation to weight loss had a greater improvement in chronic inflammation.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|